Literature DB >> 31088889

Effects of the new prescribing standards in British Columbia on consumption of opioids and benzodiazepines and z drugs.

Alexis Crabtree1, Caren Rose2, Mei Chong3, Kate Smolina4.   

Abstract

OBJECTIVE: To evaluate the effects of the 2016 College of Physicians and Surgeons of British Columbia's (CPSBC's) opioid and benzodiazepine and z drug prescribing standards on the use of these medications in British Columbia.
DESIGN: Interrupted time-series analysis of community-prescribing records over a 30-month period: January 2015 to June 2017.
SETTING: British Columbia. PARTICIPANTS: Random sample of British Columbia residents with filled prescriptions during the study period. INTERVENTION: Introduction of CPSBC's opioid and benzodiazepine and z drug prescribing standards on June 1, 2016. MAIN OUTCOME MEASURES: Total weekly consumption of opioids (measured in morphine equivalents) and benzodiazepines and z drugs (measured in diazepam equivalents); and total monthly users of each class of medication.
RESULTS: Total consumption of both medication classes began to decline in late 2015, and the rate of decrease did not statistically significantly change following the implementation of the CPSBC standards in June 2016. In contrast, introduction of the standards was associated with an immediate 2% decrease in the number of monthly users of opioids for pain (P < .001), culminating in a 9% decrease over the course of the following year (P < .001). This trend was driven largely by a decrease in the number of continuing users; minimal change was seen in the number of new users during the study period. Trends in monthly users of benzodiazepines and z drugs mirrored those seen for opioids for pain.
CONCLUSION: Implementation of the 2016 CPSBC standards did not change a pre-existing downward trend in consumption of opioids or benzodiazepines and z drugs that began 6 months earlier. However, the standards did have a small effect on the number of monthly users of these medications, with a decrease in opioid prescribing among continuing users. Given the risk of destabilization of patients who are discontinued from opioid therapy, future research should assess how patient health outcomes are related to changing prescribing practices. Copyright© the College of Family Physicians of Canada.

Entities:  

Year:  2019        PMID: 31088889      PMCID: PMC6516682     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  17 in total

1.  Today's fentanyl crisis: Prohibition's Iron Law, revisited.

Authors:  Leo Beletsky; Corey S Davis
Journal:  Int J Drug Policy       Date:  2017-07-18

2.  Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users.

Authors:  Michael I Demidenko; Steven K Dobscha; Benjamin J Morasco; Thomas H A Meath; Mark A Ilgen; Travis I Lovejoy
Journal:  Gen Hosp Psychiatry       Date:  2017-04-27       Impact factor: 3.238

3.  Ending the Opioid Epidemic - A Call to Action.

Authors:  Vivek H Murthy
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

4.  Turning the tide or riptide? The changing opioid epidemic.

Authors:  Stefan G Kertesz
Journal:  Subst Abus       Date:  2016-11-18       Impact factor: 3.716

5.  A synthesis of oral morphine equivalents (OME) for opioid utilisation studies.

Authors:  Suzanne Nielsen; Louisa Degenhardt; Bianca Hoban; Natasa Gisev
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-12-22       Impact factor: 2.890

6.  Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers.

Authors:  Catherine Barber; David Gagnon; Jennifer Fonda; Kelly Cho; John Hermos; Matthew Miller
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-08-16       Impact factor: 2.890

7.  Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015.

Authors:  Rose A Rudd; Puja Seth; Felicita David; Lawrence Scholl
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-12-30       Impact factor: 17.586

8.  Changes in Provider Prescribing Patterns After Implementation of an Emergency Department Prescription Opioid Policy.

Authors:  Scott R Osborn; Julianna Yu; Barbara Williams; Maria Vasilyadis; C Craig Blackmore
Journal:  J Emerg Med       Date:  2017-01-19       Impact factor: 1.484

9.  Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis.

Authors:  Tara Gomes; David Juurlink; Zhan Yao; Ximena Camacho; J Michael Paterson; Samantha Singh; Irfan Dhalla; Beth Sproule; Muhammad Mamdani
Journal:  CMAJ Open       Date:  2014-10-01

10.  Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis.

Authors:  Hsien-Yen Chang; Tatyana Lyapustina; Lainie Rutkow; Matthew Daubresse; Matt Richey; Mark Faul; Elizabeth A Stuart; G Caleb Alexander
Journal:  Drug Alcohol Depend       Date:  2016-06-02       Impact factor: 4.492

View more
  3 in total

1.  Trends in dispensing of individual prescription opioid formulations, Canada 2005-2020.

Authors:  Wayne Jones; Ridhwana Kaoser; David Rudoler; Benedikt Fischer
Journal:  J Pharm Policy Pract       Date:  2022-03-29

2.  Warning from Canada: Latin America, South Africa and India may face an opioid epidemic in the coming years.

Authors:  Andrea D Furlan; Alexandra M Harvey; Rashmi Chadha
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

3.  Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study.

Authors:  Dimitra Panagiotoglou; Rita McCracken; M Ruth Lavergne; Erin C Strumpf; Tara Gomes; Benedikt Fischer; Austyn Brackett; Cheyenne Johnson; Perry Kendall
Journal:  BMJ Open       Date:  2020-11-05       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.